GlycoMimetics 与 Crescent Biopharma 合并，获得 $200M 资金，并扩大肿瘤学管道。 GlycoMimetics merges with Crescent Biopharma, secures $200M funding, and expands oncology pipeline.

在宣布与 Crescent Biopharma 合并并获得 2 亿美元资金以增强其肿瘤学产品线后，GlycoMimetics 的股价大幅上涨。 GlycoMimetics shares rose significantly after announcing a merger with Crescent Biopharma and securing $200 million in funding to enhance its oncology pipeline. 合并定于2025年Q2结束,重点是固态肿瘤疗法,包括CR-001。 The merger, set to close in Q2 2025, will focus on solid tumor therapies, including CR-001. 同时,投资人权利律师公司Halper Sadeh LLC正在调查合并对GlycoMimetics股东的公平性,GlycoMimetics股东将拥有合并后合并实体的3.1%。 Meanwhile, investor rights law firm Halper Sadeh LLC is investigating the merger's fairness to GlycoMimetics shareholders, who will own around 3.1% of the combined entity post-merger.